FinEdge Labs
P

PEN

PENUnverified
2 segments tracked|2 years of data|Annual (10-K)
Total Revenue
$1.2B12.9%
FY2024
Operating Segments
2
Active segments
Blended Margin
0.0%
Operating margin
Highest Margin
0.0%
Thrombectomy
Segment Shift

Thrombectomy has grown from 64.0% to 68.3% of total revenue since FY2023, with 0.0% operating margins.

Segment Revenue Over Time

Revenue Mix

Segment Breakdown — FY2024

SegmentRevenueOp. IncomeMargin% of TotalYoY
Thrombectomy$815M$00.0%68.3%+20.4%
Embolization$379M$00.0%31.7%-0.5%

Want more? Unlock the full analysis.

Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.

Get Started Free